1.Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K et al.. (2011) Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.. Bioorg Med Chem Lett, 21 (6):(1795-801). [PMID:21316218]
2.Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R et al.. (2012) Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.. Clin Cancer Res, 18 (17):(4794-805). [PMID:22767668]
3.Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J et al.. (2014) Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.. Clin Cancer Res, 20 (16):(4251-61). [PMID:24947927]
4.Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Fujiwara Y, Tamura Y, Wakui H, Honda K, Mizugaki H, Kitazono S et al.. (2015) Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.. Invest New Drugs, 33 (3):(641-51). [PMID:25809858]
5.Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. (2013) MEK and the inhibitors: from bench to bedside.. J Hematol Oncol, 6 (3):(27). [PMID:23587417]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
